FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

GLENMARK

570
+33.05 (6.16%)
Updated 03:29 16/04 IST

GLENMARK Buy or Sell - FrontPage Forums

13 Users have submitted 14 trade ideas of Rs. 2,541,830.84 for GLENMARK
Disclaimer
93% Bullish
7% Bearish

GLENMARK Buy or Sell - Brokerage Reports

No. of reports in last year
7
No. of analysts
6
Average Consensus Forecast
514.86
Consensus Potential
-7.67%
See GLENMARK Share Price Targets >>

GLENMARK Ratings

Long term GLENMARK rating by FrontPage users
3.1/5 (7 Ratings)
Find answers to all your questions on live GLENMARK message board: Is GLENMARK buy or sell? Should I buy GLENMARK shares? Why are GLENMARK shares falling? Should I invest in GLENMARK stock?

  1. Home
  2. GLENMARK Forum

GLENMARK Share Price Discussion

D
Reputation: 5,073 • Just now
Dharun investor in GLENMARK
#GLENMARK No Algo just a Simple Script Which ...

#GLENMARK Simple Analysis with only Single line
Like
Reply
T
Reputation: 3,799 • Just now

GLENMARK LIFESCIENCES HAS FILED IPO PAPERS WITH SEBI INDIA
Like
Reply

GLENMARK - chart - 2734369
#GLENMARK No Algo just a Simple Script Which I created , 238 to Exactly Touch T2.
1
Reply

GLENMARK - chart - 2734341
#GLENMARK Informed Earlier to one of my Good Friend
1
Reply
Like
Reply
Dharun investor in GLENMARK
Trade entered: Buy GLENMARK APR21 580 CE @25.65...
Like
Reply

Type
Buy
Instrument
GLENMARK APR21 570 PE
Entry Price
₹23.95
Price@Trade
₹23.95
Target Price
₹28
Stop Price
₹21
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹27,542.5 approx for 1150 Qty
Status
Exited
Exit Price
₹23.95
Net P&L
₹0 (0%)
Like
Reply (1)
swap_vert
Trade
See all replies
Dharun investor  @Dharun
Yesterday 8:13 AM

Update
Exited
Exit Price
₹23.95
Net P&L
₹0 (0%)

Type
Buy
Instrument
GLENMARK APR21 580 CE
Entry Price
₹25.65
Price@Trade
₹25.65
Target Price
₹30
Stop Price
₹22.5
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹29,497.5 approx for 1150 Qty
Status
Exited
Exit Price
₹25.4
Net P&L
-₹287.5 (-0.97%)
Like
Reply (1)
swap_vert
Trade
See all replies
Dharun investor  @Dharun
Yesterday 8:15 AM

Update
Exited
Exit Price
₹25.4
Net P&L
-₹287.5 (-0.97%)

Type
Buy
Instrument
GLENMARK
Entry Price
₹574.35
Price@Trade
₹574.35
Target Price
₹650
Stop Price
₹560
Valid Till
May 14, 2021 3:20 AM
Margin
₹114,870 approx for 200 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
GLENMARK APR21 460 PE
Entry Price
₹1.3
Price@Trade
₹1.3
Target Price
₹50
Stop Price
₹0
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹1,495 approx for 1150 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Sell
Instrument
GLENMARK APR21 540 PE
Entry Price
₹12.25
Price@Trade
₹12.25
Target Price
₹0
Stop Price
₹20
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹261,440.71 approx for 1150 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
GLENMARK APR21 550 CE
Entry Price
₹35.95
Price@Trade
₹35.95
Target Price
₹60
Stop Price
₹20
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹41,342.5 approx for 1150 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Sell
Instrument
GLENMARK
Entry Price
₹574.35
Price@Trade
₹574.5
Target Price
₹550
Stop Price
₹579.05
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹861,525 approx for 1500 Qty
Status
Exited
Exit Price
₹568.15
Net P&L
+₹9,300 (+1.08%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 7:52 AM

Update
Trade Entered
Entry Price
₹574.35

Update
Exited
Exit Price
₹568.15
Net P&L
+₹9,300 (+1.08%)
D
Reputation: 0 • Yesterday 7:49 AM

Type
Buy
Instrument
GLENMARK APR21 FUT
Entry Price
₹576.55
Price@Trade
₹576.55
Target Price
₹750
Stop Price
₹550
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹253,057.14 approx for 1150 Qty
Status
Exited
Exit Price
₹572.2
Net P&L
-₹5,002.5 (-1.98%)
Like
Reply (1)
swap_vert
Trade
See all replies
DK SINGH @dksing
Yesterday 8:45 AM

Update
Exited
Exit Price
₹572.2
Net P&L
-₹5,002.5 (-1.98%)

Type
Buy
Instrument
GLENMARK
Entry Price
₹575.4
Price@Trade
₹574.6
Target Price
₹585
Stop Price
₹573
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹57,540 approx for 100 Qty
Status
Exited
Exit Price
₹571.8
Net P&L
-₹360 (-0.63%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 7:49 AM

Update
Trade Entered
Entry Price
₹575.4
Siva @siva-BJxOfuxBO
Yesterday 7:55 AM

Update
Exited
Exit Price
₹571.8
Net P&L
-₹360 (-0.63%)

Type
Buy
Instrument
GLENMARK APR21 600 CE
Entry Price
₹18.75  ₹18.35
Price@Trade
₹18.6
Target Price
₹40
Stop Price
₹10  10.2
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹211,025 approx for 11500 Qty
Status
Active
Like
Reply (3)
swap_vert
Trade
See all replies
Govind Suthar @govindsuthar
Yesterday 7:48 AM

Update
Entry Price Modified
Price @ Update
₹18.6
Original Entry Price
₹18.75
New Entry Price
18.35
TrackerBot @trackerbot
Yesterday 7:49 AM

Update
Trade Entered
Entry Price
18.35
Govind Suthar @govindsuthar
Yesterday 7:51 AM

Update
Stoploss Trailed
Price @ Update
₹17.45
Original SL
₹10
New SL
10.2

Type
Buy
Instrument
GLENMARK APR21 580 CE
Entry Price
₹24.9
Price@Trade
₹24.9
Target Price
₹50
Stop Price
₹20
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹28,635 approx for 1150 Qty
Status
Exited
Exit Price
₹22.75
Net P&L
-₹2,472.5 (-8.63%)
Like
Reply (1)
swap_vert
Trade
See all replies
Rishabh  @rishabh918
Yesterday 8:23 AM

Update
Exited
Exit Price
₹22.75
Net P&L
-₹2,472.5 (-8.63%)
EQUITY AND OPTION TRADER in GLENMARK
#GLENMARK 600 CE CMP 14 Buy above 15 for targe...
Like
Reply

Sold #GLENMARK options - GLENMARK21APR560CE at 0.00
Like
Reply

Type
Buy
Instrument
GLENMARK APR21 600 CE
Entry Price
₹18.25
Price@Trade
₹17.65
Target Price
₹30
Stop Price
₹9
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹20,987.5 approx for 1150 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 7:42 AM

Update
Trade Entered
Entry Price
₹18.25
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • GLENMARK - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization14,876.17
    Enterprise Value17,679.79
    Price to Earnings14.67
    Price to Book Value1.43
    Return on Capital Employed0.11
    Return on Equity0.1
    Face Value1
    Dividend YieldNA
  • GLENMARK - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    15-Feb-21ICICIdirect.comBuy635
    7-Dec-20EdelweissBuy559
    27-Nov-20Geojit Financial ServicesBuy548
    10-Nov-20Nirmal BangBuy578
    9-Nov-20Prabhudas LilladherSell424
    GLENMARK Brokerage Price Target
  • GLENMARK Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Apr 16539.95578525.65571.9
    Apr 15514.85553.2512.4536.95
    Apr 13507519.4484.85511.35
    Apr 12532537492.8497.95
    Apr 9505534.3505529.65
  • GLENMARK Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹485.3
    30 Day Moving Average₹482.66
    50 Day Moving Average₹485.59
    100 Day Moving Average₹493.22
    200 Day Moving Average₹480.86
  • GLENMARK - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue6,4037,989.23-0.2
    Operating Profit1,3472,662.19-0.49
    Profit Before Tax1,2192,552.9-0.52
    Net Income1,0142,140.61-0.53
  • GLENMARK - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds10,3919,436.620.1
    Total Liabilities5,2694,790.480.1
    Total Assets15,66114,227.10.1
  • GLENMARK - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,124877.720.28
    Cash from Investing Activity-1,137-2,580.46-0.56
    Cash from Financing Activity-621,879.38-1.03
    Net Cash Flow-75176.64-1.42
  • GLENMARK - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.15
    Return on Equity0.10.23
    Return on Capital Employed0.110.22
  • GLENMARK - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.23
    3 Year CAGR Growth in Operating Profit0.04
    3 Year CAGR Growth in EBIDTA0.11
    3 Year CAGR Growth in Net Income0.01
    3 Yr CAGR Growth - Diluted EPS-0.03
  • GLENMARK - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.16
    5 Year CAGR Growth in Operating Profit3.05
    5 Year CAGR Growth in EBIDTA2.4
    5 Year CAGR Growth in Net Income1.63
    3 Yr CAGR Growth - Diluted EPS1.52
  • GLENMARK - Recent News

    keyboard_arrow_down
    NewsBot
    Apr 8 4:26 AM
    Buy Glenmark Pharma, target price Rs 517: ICICI Direct
    The Economic Times
    NewsBot
    Apr 1 11:11 AM
    F&O: Nifty forms higher highs, crosses recent swing high in hope for the bulls
    The Economic Times
    NewsBot
    Mar 23 8:11 AM
    Glenmark gets USFDA nod for generic high blood pressure drug
    The Economic Times
    NewsBot
    Mar 9 8:43 AM
    Glenmark Pharma Looking To Unlock Value Of API Arm Via IPO Route In 2021
    Moneycontrol
    NewsBot
    Feb 22 5:26 AM
    Glenmark arm gets Russian health ministry nod for nasal spray Ryaltris
    The Economic Times
    NewsBot
    Feb 22 4:23 AM
    Glenmark Arm Gets Russian Health Ministry Nod For Nasal Spray Ryaltris
    Moneycontrol
    NewsBot
    Feb 18 4:23 AM
    Buy Glenmark Pharmaceuticals; Target Of Rs 635: ICICI Direct
    Moneycontrol
    NewsBot
    Feb 16 5:21 AM
    Glenmark launches kidney cancer treatment drug in India priced 96% lower than innovator brand
    The Economic Times
    NewsBot
    Feb 13 6:01 AM
    Glenmark Q3 results: Net profit up 30% at Rs 248 cr
    The Economic Times
    NewsBot
    Feb 11 5:11 AM
    Glenmark gets USFDA nod for acne treatment drug
    The Economic Times
  • GLENMARK - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • GLENMARK - More Information

    keyboard_arrow_down

    Glenmark Pharmaceuticals Ltd:
    Glenmark Pharmaceuticals, a company that deals with pharmaceutical products, was established in 1977 by Gracias Saldanha which headquarter is in Mumbai, India. It manufactures generic drugs and various active pharmaceutical ingredients.
    The company was named after the name of his two sons, Glenn and Mark. In the beginning, the company used to sell the products in India, Africa, and Russia. The company came to the public in the year 1999, and also took some procedures and built its research facility for the first time. Glenmark Saldanha’s elder son Glenn had the invasion as the CEO of the company in 2001 after working at PricewaterhouseCoopers when he came back to India.
    In 2008, Glenmark became the fifth-biggest company for pharmaceuticals in India. Glenmark entered into the market of dermatology by launching ‘Candid Cream’. Dermatology is one of the key focus areas of Glenmark, until today.
    About Company Information:
    The company entered the market of dermatology by launching Candid Cream in 1979, at the very beginning. In 1980, the company began to export their products outside of the country. In 1983, it incorporated its manufacturing facility for the very first time at Nasik, Maharashtra.
    The R&D department was founded in the plant at Nasik in 1984. The company introduced Ascoril in the market in 1987. The company initiated operating its business in Srilanka, Afghanistan, Mauritius, and Kenya in 1989. It expanded the plant at Nasik in 1992. It integrated a wholly possessed subordinate company, Glenmark Exports Pvt Ltd to strengthen its position internationally in the market of pharmaceuticals in 1996.
    In Brazil, the company started to sell pharmaceutical products in 1999. The company entered into the segment of diabetes in 2000. The company initiated the business of manufacturing API in 2001. It obtained a facility of API manufacturing from Glaxosmithkline Pharmaceuticals at Ankleshwar, Gujarat in 2002. Glenmark has done its out-licensing deal for the first time to discover R&D in 2004.
    The company commissioned a new facility for manufacture at Baddi, Himachal Pradesh in 2005. It signed an out-licensing contract with Merk KGaA, Germany in 2006, for Melogliptin. The company received the approval of MHRA, the UK for their plant at Baddi in 2007.
    The company re-organized its business and integrated a company namely Glenmark Generics as its subordinate one in 2008. During 2009-10, it integrated Glenmark Generics B.V. in the Netherlands. Glenmark signed the Development Agreement with Forest Laboratories to collaborate on Novel Agents.
    The company made the announcement of launching a cream namely Hydrocortisone Butyrate in the US, in 2013. Glenmark brought together its two subsidiary companies which are Glenmark Generics Ltd. and Glenmark Access Ltd. with GPL in the year 2014. The company disclosed its approval and launching of Verapamil and Trandolapril Hydrochloride in 2015.
    Glenmark announced the strategic blueprint of its evolution to an innovation-led globally spread pharmaceutical organization on 19th December 2016. The blueprint bears its greater alignment of business spreading generics to give priority mostly to the research and development efforts in three core therapeutic sections: respiratory, oncology and dermatology.
    The company announced affirmative results for GSP 301 on 30th March 2017. The company has also announced that it has submitted an NDA to the FDA of US for Ryaltris, the respiratory pipeline candidate, which is basically a tentative fixed-dose nasal spray which is a combination of a steroid and an antihistamine that is used for treatment of seasonal allergic rhinitis (SAR) and it was announced on 22nd May 2018.
    The company announced on 19th June 2018 that the first supplemental Abbreviated New Drug Application (SANDA) was provided by the US Food and Drug Administration for the manufacturing facility of the company in Monroe, New Carolina. The Monroe facility in New Carolina is the first manufacturing plant of Glenmark in the US which is founded to manufacture various pharmaceutical products of fixed does. The company has made an investment of more than $100 million on that facility along with some planning of further development in upcoming years.
    How Glenmark Pharmaceuticals Ltd is categorised as Pharmaceuticals and Health Care Sector and Pharmaceuticals Industry.
    Pharmaceuticals and Health care sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more. The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Glenmark Pharmaceuticals Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Glenmark Pharmaceuticals Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020